Document:

Exhibit 10.1

 

AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT

 

AMENDMENT NO. 1 TO SECURITIES
PURCHASE AGREEMENT, dated as of January 14, 2022 (this “Amendment”), among SCOPUS BIOPHARMA INC., a Delaware corporation
(the “Company”) and the Purchaser signatory hereto. Capitalized terms used and not otherwise defined herein shall have
the meanings set forth in the Purchase Agreement, as defined herein.

 

W I T N E S S E T H:

 

WHEREAS, on November 21, 2021,
the Company entered into the Securities Purchase Agreement, (the “Existing Purchase Agreement”) with the purchasers
identified on the signature pages thereto (the “Purchasers”); and

 

WHEREAS, the Company has requested
that the Purchaser, severally and not jointly with the other Purchasers, amend the Existing Purchase Agreement as more specifically set
forth herein (the Existing Purchase Agreement, as amended by this Amendment, and as the same may be amended, restated, modified and/or
supplemented from time to time being referred to as the “Purchase Agreement”);

 

NOW, THEREFORE, in consideration
of the agreements herein contained, and for other valuable consideration the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows.

 

ARTICLE
1. AMENDMENTS. Effective as of the date hereof, the Existing Purchase Agreement shall be amended in the manner
set forth below.

 

(a)              
Section 1.1.

 

(i)                
The definition of “Authorized Share Increase Date” in Section 1.1 is hereby amended to replace the existing
definition with the following:

 

““Authorized Share Increase
Date” means the date the initial Registration Statement covering all of the Shares and the AIO Shares has been declared effective
by the Commission.”

 

(ii)             
The definition of “Effective Date” in Section 1.1 is hereby amended to delete the phrase “, after the Authorized
Share Increase Date,”.

 

(b)              
Section 4.11. The text of Section 4.11(b) is hereby deleted and replaced with “[Intentionally Omitted].”

 

(c)              
Section 4.12. The text of Section 4.12 is hereby deleted and replaced with “[Intentionally Omitted].”

 

     

     

    

 

ARTICLE
2. MISCELLANEOUS.

 

2.1             
 Counterparts. This Amendment may be executed in counterparts and by different parties hereto in separate counterparts,
each of which, when executed and delivered, shall be deemed to be an original and all of which, when taken together, shall constitute
one and the same instrument. A photocopied, facsimile or pdf signature shall be deemed to be the functional equivalent of a manually executed
original for all purposes.

 

2.2             
Ratification. Except as set forth in Article 1, no amendment is intended hereby. The Existing Purchase Agreement,
as amended by this Amendment, and the other agreements, documents and instruments delivered in connection with the Existing Purchase Agreement
(and/or in connection with this Amendment) are, and shall continue to be, in full force and effect, and each of the parties hereto hereby
confirms, approves and ratifies in all respects the Existing Purchase Agreement, as amended by this Amendment, and each of the other agreements,
documents and instruments delivered in connection with the Existing Purchase Agreement (and/or in connection with this Amendment).

 

2.3             
WAIVER OF JURY TRIAL. WITHOUT LIMITING IN ANY WAY SECTION 5.22 OF THE PURCHASE AGREEMENT, IN ANY ACTION, SUIT,
OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

2.4              GOVERNING
LAW. All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of
the transactions contemplated by this Amendment (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any this Amendment), and
hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by
mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in
any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of this Amendment,
then, in addition to the obligations of the Company under Section 4.10 of the Purchase Agreement, the prevailing party in such
Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.

 

2.5             
References. From and after the effective date of this Amendment, each reference in the Purchase Agreement to “this
Agreement”, “hereof”, “hereunder” or words of like import, and all references to the Purchase Agreement
in any and all agreements, instruments, certificates and other documents relating to the Purchase Agreement, shall be deemed to mean the
Purchase Agreement as modified and amended by this Amendment and as the same may be further amended, modified or supplemented in accordance
with the terms thereof.

 

[Signature pages follow]

 

     

     

    

 

IN
WITNESS WHEREOF, the undersigned have caused this Amendment to be duly executed by their respective, duly authorized officers as of the
date first above written.

 

	 	SCOPUS
    BIOPHARMA INC.
	 	 
	 	 
	 	By:	 
	 	Name:  	              
	 	Title:	 

 

[PURCHASER SIGNATURE PAGE FOLLOWS]

 

[Signature Page to Amendment No. 1 to the Securities
Purchase Agreement]

 

     

     

    

 

[SECURITIES PURCHASE AGREEMENT AMENDMENT NO. 1]

 

Name of Purchaser: ____________________________________________________

 

Signature of Authorized Signatory of Purchaser: __________________________

 

Name of Authorized Signatory: ____________________________________

 

Title of Authorized Signatory: _____________________________________

 

[Signature Page to Amendment No. 1 to the Securities
Purchase Agreement]Exhibit 10.2

 

AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT

 

AMENDMENT NO. 1 TO REGISTRATION
RIGHTS AGREEMENT, dated as of January 14, 2022 (this “Amendment”), among SCOPUS BIOPHARMA INC., a Delaware corporation
(the “Company”) and the holder signatory hereto (the “Holder”). Capitalized terms used and not otherwise
defined herein shall have the meanings set forth in the Registration Rights Agreement, as defined herein.

 

W I T N E S S E T H:

 

WHEREAS, on November 21, 2021,
the Company entered into the Registration Rights Agreement, (the “Existing Registration Rights Agreement”) with the
holders identified on the signature pages thereto (collectively, the “Holders”); and

 

WHEREAS, the Company has requested
that the Holder, severally and not jointly with the other Holders, amend the Existing Registration Rights Agreement as more specifically
set forth herein and amendments entered into by the other Holders (the Existing Registration Rights Agreement, as amended by this Amendment,
and as the same may be amended, restated, modified and/or supplemented from time to time being referred to as the “Registration
Rights Agreement”);

 

NOW, THEREFORE, in consideration
of the agreements herein contained, and for other valuable consideration the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows.

 

ARTICLE
1. AMENDMENTS. Effective as of the date hereof, the Existing Registration Rights Agreement shall be amended in
the manner set forth below.

 

(a)              
Section 1

 

(i)                
The definition of “Effectiveness Date” in Section 1 is hereby amended to replace the existing definition with
the following:

 

““Effectiveness
Date” means, with respect to the Registration Statement required to be filed hereunder, February 15, 2022 (or, in the
event of a “full review” by the Commission, the 10th day following the date the Company is notified by the
Commission that the Registration Statement will not be reviewed and is no longer subject to further review and comment, provided,
that, if such 10th day is on or after February 14, 2022, the Effectiveness Date shall be no earlier than April 1,
2022, and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or
Section 3(c), the 60th calendar day following the date on which an additional Registration Statement is required to be
filed hereunder; provided, however, that in the event the Company is notified by the Commission that one or more of the
above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as
to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date
precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a Trading Day,
then the Effectiveness Date shall be the next succeeding Trading Day.”

 

     

     

    

 

ARTICLE
2. MISCELLANEOUS.

 

2.1             
Counterparts. This Amendment may be executed in counterparts and by different parties hereto in separate counterparts,
each of which, when executed and delivered, shall be deemed to be an original and all of which, when taken together, shall constitute
one and the same instrument. A photocopied, facsimile or pdf signature shall be deemed to be the functional equivalent of a manually executed
original for all purposes.

 

2.2             
Ratification. Except as set forth in Article 1, no amendment is intended hereby. The Existing Registration Rights
Agreement, as amended by this Amendment, and the other agreements, documents and instruments delivered in connection with the Existing
Registration Rights Agreement (and/or in connection with this Amendment) are, and shall continue to be, in full force and effect, and
each of the parties hereto hereby confirms, approves and ratifies in all respects the Existing Registration Rights Agreement, as amended
by this Amendment, and each of the other agreements, documents and instruments delivered in connection with the Existing Registration
Rights Agreement (and/or in connection with this Amendment).

 

2.3             
WAIVER OF JURY TRIAL. WITHOUT LIMITING IN ANY WAY SECTION 5.22 OF THE PURCHASE AGREEMENT, IN ANY ACTION, SUIT,
OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

2.4             
GOVERNING LAW. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be determined in accordance with the provisions of the Purchase Agreement.

 

2.5             
References. From and after the effective date of this Amendment, each reference in the Registration Rights Agreement
to “this Agreement”, “hereof”, “hereunder” or words of like import, and all references to the Registration
Rights Agreement in any and all agreements, instruments, certificates and other documents relating to the Registration Rights Agreement,
shall be deemed to mean the Registration Rights Agreement as modified and amended by this Amendment and as the same may be further amended,
modified or supplemented in accordance with the terms thereof.

 

[Signature pages follow]

 

[Signature Page to Amendment No. 1 to the Registration
Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, the undersigned have caused this Amendment to be duly executed by their respective, duly authorized officers as of the
date first above written.

 

	 	SCOPUS
    BIOPHARMA INC.
	 	 
	 	 
	 	By:	 
	 	Name:  	              
	 	Title:	 

 

[Holder Signature Page follows]

 

[Signature Page to Amendment No. 1 to the Registration
Rights Agreement]

 

     

     

    

 

[SIGNATURE
PAGE OF HOLDERS TO scps RRA Amendment]

 

 

Name of Holder: __________________________

 

Signature of Authorized Signatory of Holder: __________________________

 

Name of Authorized Signatory: _________________________

 

Title of Authorized Signatory: __________________________

 

[SIGNATURE PAGES CONTINUE]

 

[Signature Page to Amendment No. 1 to the Registration
Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]